Gilead (GILD) Q1 FY25 earnings call

Gilead delivered a solid first quarter with robust growth in its base business, particularly HIV, despite headwinds from Medicare Part D redesign and competitive pressures in cell therapy. The company highlighted significant pipeline advancements, including positive Phase III data for Trodelvy and an anticipated FDA decision for lenacapavir for PrEP, positioning it for multiple potential launches and sustained top-line growth beyond 2025.